Real-life treatment persistence and treatment outcomes of Finnish patients with inflammatory bowel disease receiving vedolizumab as first-line biological treatment.
Ylisaukko-Oja T, Af Björkesten CG, Eberl A, Nuutinen H, Jussila A, Molander P, Koskela R, Blomster T, Pajala M, Ilus T, Haiko P, Kovac B, Silvola S, Smith S, Jokelainen J, Sipponen T.
Ylisaukko-Oja T, et al. Among authors: kovac b.
Heliyon. 2024 Jun 4;10(12):e32432. doi: 10.1016/j.heliyon.2024.e32432. eCollection 2024 Jun 30.
Heliyon. 2024.
PMID: 38975101
Free PMC article.